FDA reform needs to be underpinned by strategy, not ‘indiscriminate’ cuts The Trump administration could save the lives of ...

Q4 2024 Earnings Call Transcript February 27, 2025 Cardiff Oncology, Inc. beats earnings expectations. Reported EPS is $-0.22 ...

After two years in the shadows, health stocks are back as a haven for investors navigating economic uncertainty.

Eisai plans to lay off 121 employees in the U.S. A former deputy director of China's drug agency is under investigation by ...

The Trump administration has canceled an upcoming meeting of the Food and Drug Administration’s vaccine advisory committee, a ...

Each year, flu vaccines are tailored to match the most prevalent virus strains expected to circulate. Without an official ...

Revolving door is a VERY polite term for Patrizia Cavazzoni's moves. Then again, she has a 25-year history of picking Big Pharma over vulnerable patients. She'll fit right in with Scott Gottlieb.

In a Chinese trial, trastuzumab rezetecan induced a 73% response rate in previously treated HER2-mutant non-small cell lung cancer (NSCLC). The safety profile of the novel antibody-drug conjugate was ...

Artificial intelligence improves process control and reduces the time required to produce key products such as the COVID-19 ...

SpringWorks Therapeutics sprung out of Pfizer’s storeroom, when a rare disease advocacy group pushed to keep a program for ...